The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions

The distinction of benign from malignant mesothelial proliferations in cytologic specimens can be problematic. In this study, the authors investigated the utility of immunohistochemical (IHC) markers in making this distinction.

[1]  A. Böcking,et al.  Diagnostic and Prognostic Value Of Ki67 Proliferation Fraction in Serous Effusions , 2004, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[2]  M. Lind,et al.  Expression of Bcl-2 Family Members in Malignant Pleural Mesothelioma , 2006, Acta oncologica.

[3]  D. Ruiter,et al.  Coexpression of intermediate filament polypeptides in human fetal and adult tissues. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[4]  K. Gatter,et al.  Immunohistological staining of reactive mesothelium, mesothelioma, and lung carcinoma with a panel of monoclonal antibodies. , 1987, Journal of clinical pathology.

[5]  Kenji Suzuki,et al.  Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma , 2007, Modern Pathology.

[6]  A. Paulino,et al.  Diagnostic Use of Muscle Markers in the Cytologic Evaluation of Serous Fluids , 2002, Applied immunohistochemistry & molecular morphology : AIMM.

[7]  G. Pinkus,et al.  Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. , 2009, American journal of clinical pathology.

[8]  M. McNutt,et al.  Reactive and Neoplastic Serosal Tissue: A Light-Microscopic, Ultrastructural, and Immunocytochemical Study , 1986, The American journal of surgical pathology.

[9]  R. Attanoos,et al.  The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2 , 2003, Histopathology.

[10]  J. Said,et al.  Epithelial membrane antigen in the cytodiagnosis of effusions and aspirates: Immunocytochemical and ultrastructural localization in benign and malignant cells , 1987, Diagnostic cytopathology.

[11]  W. Travis,et al.  The separation of benign and malignant mesothelial proliferations. , 2000, The American journal of surgical pathology.

[12]  J..  Diagnostic Immunohistochemistry , 2022 .

[13]  K. Metze,et al.  The use of epithelial membrane antigen and silver‐stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses , 1998, Cancer.

[14]  M. Masjedi,et al.  The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations. , 2009, Archives of pathology & laboratory medicine.

[15]  A. Nicholson,et al.  The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis , 1999, The Journal of pathology.

[16]  F. Galateau-Sallé,et al.  The Separation of Benign and Malignant Mesothelial Proliferations , 2000, Archives of pathology & laboratory medicine.

[17]  A. Nassar,et al.  Diagnostic utility of D2‐40 and podoplanin in effusion cell blocks , 2007, Diagnostic cytopathology.

[18]  J. Hurlimann.  Desmin and neural marker expression in mesothelial cells and mesotheliomas. , 1994, Human pathology.

[19]  M. Duggan,et al.  Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin. , 1987, Acta cytologica.

[20]  P. Hasleton,et al.  Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports , 2006, Histopathology.